Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019163 (
hepatitis B
)
38,309
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A continuous adherent cell line was established from a hepatocellular carcinoma of an HBsAg-positive Italian male. This cell line, designated Tong/HCC, has been grown in a hormone-supplemented medium for more than 18 months. The cell line secretes HBsAg,
alpha-fetoprotein
, albumin and alpha 1-antitrypsin. alpha-Fetoprotein production is enhanced by the addition of hydrocortisone and appears to be glucocorticoid concentration-dependent. The concentrates of the supernatant from the cell cultures and cell lysates were negative when tested for HBeAg. The cell culture medium was negative for
hepatitis B
virus DNA when tested by dot-blot hybridization. However,
hepatitis B
virus DNA was found to be integrated in the chromosomal DNA by Southern blot analysis. At least five different integration sites were identified, and no free
hepatitis B
virus DNA was observed. The modal chromosome number was 64, and a translocation on Chromosome 15 was consistently noted. HLA typing revealed sites for A3, Aw24, Bw34 and Cw1.
...
PMID:Characteristics of a cell line (Tong/HCC) established from a human hepatocellular carcinoma. 244 44
Hepatocellular carcinoma is the most frequent cancer worldwide, responsible for approximately 1,000,000 deaths annually, most of them in the Far East and in sub-Saharan Africa. It usually presents at an advanced stage and has a poor prognosis. There is evidence of an etiologic role for
hepatitis B
virus infection in the etiology of hepatocellular carcinoma. Carriers of the virus are 94 times more at risk for hepatocellular carcinoma than noncarriers. In many cases
hepatitis B
virus DNA is integrated within the cellular genome of the tumor. Programs have been established to detect hepatocellular carcinoma at an early stage; persons at high risk are regularly screened by measurement of serum
alpha-fetoprotein
levels and ultrasound examination of the liver. Surgical resection offers the only hope of cure at present, as chemotherapy, radiotherapy, and immunotherapy have not shown promise. Ideally, surgery should be done on small asymptomatic tumors.
...
PMID:NIH conference. Hepatocellular carcinoma. 244 10
A hepatocellular carcinoma was found in the cirrhotic liver of a 45-year-old man in the absence of previous
hepatitis B
and with a normal
alpha-fetoprotein
level in serum. This is contrasted with the case of a 57-year-old man with "typical" findings of a hepatocellular carcinoma in a small-nodular cirrhotic liver after viral hepatitis B and markedly elevated
alpha-fetoprotein
.
...
PMID:[Variable clinical symptoms of hepatocellular carcinoma]. 244 23
Primary liver carcinoma (PLC) may express a certain number of markers. Here we communicate results of an analysis of five such markers (alpha-1-antitrypsin--AAT--, carcino-embryonic antigen --CEA--,
alpha-fetoprotein
--AFP--, and superficial --HBsAg-- and core --HBcAg-- antigens of
hepatitis B
virus) by means of PAP techniques in 130 cases of PLC, comparing the neoplastic tissue and the non-tumorous liver. Three variants of PLC are distinguished: hepatocarcinoma (HC) (108 cases); cholangiocarcinoma (CC) (19 cases); and three cases of hepatocholangiocarcinoma (HCC). AAT was positive in 29 HC, 2 HCC, and negative in all 19 CC. CEA appeared positive in 16 HC, 16 CC and only one HCC. AFP was positive in two HC, and negative in all CC and HCC. HBsAg displayed positivity in 15 HC and one HCC, being negative in all 19 CC. HBcAg was positive in 4 HC, and negative in all CC and HCC. HBsAg was also positive in two neoplastic emboli associated with HC. On the non-tumorous liver tissue the immunohistochemical results showed positivity for AAT and CEA, but not for AFP. Therefore the present results confirm that in the geographical area from which these tumors proceed, PLC is closely correlated with HBsAg positivity and with cirrhosis.
...
PMID:Immunohistochemical characterization of 130 cases of primary hepatic carcinomas. 244 80
Antibody profiles for
hepatitis B
virus (HBV), hepatitis A virus (HAV), cytomegalovirus (CMV), Epstein-Barr virus (EBV) and human immunodeficiency virus (HIV) were determined on 55 serum samples collected from patients with chronic renal failure who were on long-term haemodialysis for periods ranging from 8 months to 5 years and 3 months. The exposure rates for HBV, HAV, CMV, EBV and HIV were 94.5%, 100%, 94.5%, 94.5% and 0% respectively. Among the 7 HBsAg carriers, 1 and 3 were positive for e antigen (HBeAg) and antibody to HBeAg (anti-HBe), respectively and three negative for both. These 7 carriers were also negative for anti-delta antibody. A comparison of the above antiviral profiles to those of voluntary blood donors and general population in this district revealed tht there is no difference for HBV, HAV, CMV and EBV exposure rates, VDRL,
alpha-fetoprotein
and CEA were also tested and the results showed no abnormalities. Only 3 patients had abnormally elevated SGOT and SGPT levels; the causes were undetermined because all of them gave positive HBV, HAV, CMV and EBV antibody profiles. In conclusion the screening of HBsAg and VDRL in the blood banks virtually eliminated possible infections of HBV and spirochate by blood transfusion and the patients with chronic renal failure who are maintained on long-term haemodialysis are generally not at higher risks of hepatitis-related viral infections.
...
PMID:[Hepatitis-related viral markers in patients under long-term hemodialysis]. 245 21
Hepatocellular carcinoma is a very malignant tumor that affects both Caucasian and Oriental populations. In the Caucasian patient, it frequently arises in a background of cirrhosis, most commonly the alcoholic type. In the present study, the alpha-feto-protein level was increased in less than half of the Caucasian patients. In comparison, hepatocellular carcinoma in Oriental patients most often occurs in livers with postinfectious cirrhosis. In the present study, both
hepatitis B
surface antigen and an increased
alpha-fetoprotein
level were present in three of four patients. If the tumor is present, however, it appears to behave similarly in both ethnic groups. Without resection, the prognosis is poor, regardless of the presence or absence of underlying cirrhosis or
hepatitis B
surface antigen status. A tissue diagnosis of hepatocellular carcinoma is most readily made by ultrasonographically guided fine-needle aspiration, which has an 81 percent sensitivity. The most important factor affecting survival is surgical resection. Clearly, the stage at diagnosis is also crucial, but even in more advanced disease, operation can improve survival. It also appears that an increased carcinoembryonic antigen level above normal or a markedly increased
alpha-fetoprotein
level or both are associated with poor survival. However, whether this is a reflection of tumor size alone, or in fact represents a more aggressive tumor is uncertain and will require further study.
...
PMID:Hepatocellular carcinoma. A comparison of Oriental and Caucasian patients. 245 24
Seventy HBsAg-positive patients, including 24 with primary hepatocellular carcinoma, 34 with chronic active hepatitis, 12 with chronic persistent hepatitis and 30 asymptomatic healthy
hepatitis B
virus carriers were tested for anti-HBc IgM using the Corzyme-M test. Anti-HBc IgM was detected in 50% of the primary hepatocellular carcinoma patients, 26.5% of the chronic active hepatitis patients, 25% of the chronic persistent hepatitis patients, but in none of the healthy
hepatitis B
virus carriers. There was no correlation between the presence of anti-HBc IgM and HBeAg,
hepatitis B
virus DNA, ALT or
alpha-fetoprotein
levels in either the chronic active hepatitis or chronic persistent hepatitis patients. However, a significantly higher positive rate of anti-HBc IgM was noted in the HBeAg-positive or HBV DNA-positive primary hepatocellular carcinoma patients than in those with negative markers of viral replication, but no correlation was noted between the presence of anti-HBc IgM and serum ALT or
alpha-fetoprotein
levels in these primary hepatocellular carcinoma patients. Also, no differences in positivity for HBeAg, HBV DNA or levels of serum ALT were noted when patients with high titers of anti-HBc IgM were compared to those with low titers. Thus, anti-HBc IgM cannot distinguish between HBsAg-positive patients with chronic active hepatitis, chronic persistent hepatitis or primary hepatocellular carcinoma, does not correlate with serum ALT or
alpha-fetoprotein
levels and is only associated with markers for viral replication in primary hepatocellular carcinoma patients. Based on this, anti-HBc IgM appears to have a limited usefulness for diagnosis of either chronic hepatitis B or primary hepatocellular carcinoma.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Is anti-HBc IgM a useful clinical test in patients with HBsAg-positive chronic hepatitis or primary hepatocellular carcinoma? 245 29
Hepatocellular dysplasia, first described by Anthony et al. [J. clin. Path. 26: 217-223, 1973], is considered a peculiar pattern of proliferation process mainly observable in cirrhotic nodules in patients with hepatocellular carcinoma. Its precancerous meaning has been variously evaluated in the past. In the present study, immunohistochemical data concerning the presence of
alpha-fetoprotein
, alpha 1-antitrypsin, carcinoembryonic antigen,
hepatitis B
surface antigen and
hepatitis B
core antigen did not show meaningful differences between carcinomatous cells and normal and dysplastic hepatocytes. On the contrary, morphometric analysis seems to be useful to discriminate dysplastic cells by means of parametrical indexes of shape and symmetry of the nuclei and could probably offer in the future an objective evaluation of hepatocellular dysplasia.
...
PMID:Hepatocellular dysplasia: immunohistochemical and morphometrical evaluation. 245 30
During development cell types arise through the activation or repression of classes of specific genes. One hypothesis is that this phenomenon is realized by tissue-specific factors playing a role at the transcription level. Recently we have described a liver-specific nuclear protein, hepatocyte nuclear factor 1, that appears to be involved in the transcription of the fibrinogen and alpha 1-antitrypsin genes. In this report we describe the purification of hepatocyte nuclear factor 1 and demonstrate that it interacts with essential promoter regions of many liver-specific genes, including albumin,
alpha-fetoprotein
, and transthyretin. This finding suggests that hepatocyte nuclear factor 1 could be one factor necessary for establishing the liver phenotype. We also show that this protein binds to the promoter of the surface-antigen gene of the
hepatitis B
virus, a virus characterized by a high degree of hepatotropism.
...
PMID:Purified hepatocyte nuclear factor 1 interacts with a family of hepatocyte-specific promoters. 246 Aug 58
A panel of six murine monoclonal antibodies against hepatocellular carcinoma-associated antigens, reactive with PLC/PRF/5 human hepatoma cells, was conjugated to Adriamycin (doxorubicin) via a dextran bridge. This library of antibodies includes three monoclonal antibodies against
hepatitis B
virus surface antigen, one anti-
alpha-fetoprotein
, and two other IgG2a antibodies against PLC/PRF/5 hepatoma-associated antigens. The use of dextran for conjugation of Adriamycin to antibodies enabled a 5- to 10-fold amplification of the number of drug molecules linked to antibody. Conjugation of Adriamycin to dextran caused an occasional reduction in the pharmacologic activity of dextran-Adriamycin in [3H]thymidine incorporation assays in hepatoma cells as compared to nonconjugated Adriamycin. This loss of anticellular activity was partially compensated for by conjugation of specific antibodies to the dextran-Adriamycin conjugate. Conjugated compounds completely retained their binding activity to purified
hepatitis B
virus surface antigen and
alpha-fetoprotein
fixed to a solid matrix as compared to binding of homologous nonconjugated antibodies. However, some reduction of the binding activity to intact hepatoma cells was observed in three of six conjugates. Binding activity to hepatoma cells and, as a consequence, suppression of tumor cell DNA synthesis by the various conjugates was enhanced as compared to the same effect in treated colorectal carcinoma cells that do not express the relevant hepatoma-associated proteins. Furthermore, two conjugates containing nonspecific antibodies did not bind to hepatoma cells and caused minimal suppression of DNA synthesis. These results suggest that this panel of monoclonal antibody-dextran-Adriamycin conjugates was effective in suppression of PLC/PRF/5 cell growth in vitro.
...
PMID:Doxorubicin conjugates of monoclonal antibodies to hepatoma-associated antigens. 246 Aug 65
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>